Stock AIM AIM IMMUNOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:10:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.4282 USD +5.34% Intraday chart for AIM ImmunoTech Inc. -7.91% -2.66%
Apr. 10 AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer CI
Apr. 02 Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4.496 72.83 44.02 15 21.49 21.37 - -
Enterprise Value (EV) 1 4.496 72.83 44.02 15 21.49 21.37 21.37 21.37
P/E ratio -0.21 x -3.98 x -2.3 x -0.78 x -0.73 x -0.79 x -0.91 x -0.78 x
Yield - - - - - - - -
Capitalization / Revenue 32.1 x 447 x 326 x 106 x 106 x - 8.31 x 5.59 x
EV / Revenue 32.1 x 447 x 326 x 106 x 106 x - 8.31 x 5.59 x
EV / EBITDA - - - - - - - -
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book 0.44 x 1.23 x 0.78 x 0.39 x - - - -
Nbr of stocks (in thousands) 8,264 40,686 47,849 48,082 48,842 49,901 - -
Reference price 2 0.5440 1.790 0.9200 0.3119 0.4399 0.4282 0.4282 0.4282
Announcement Date 3/30/20 3/31/21 3/31/22 3/31/23 4/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.14 0.163 0.135 0.141 0.202 - 2.57 3.82
EBITDA - - - - - - - -
EBIT 1 -12.44 -15.02 -17.06 -19.92 -31.92 -27 -28.38 -32.65
Operating Margin -8,887.86% -9,212.88% -12,636.3% -14,129.79% -15,800% - -1,104.16% -854.69%
Earnings before Tax (EBT) 1 -9.533 -14.4 -19.13 -19.44 -28.96 -27 -28.64 -34.69
Net income 1 -9.533 -14.4 -19.13 -19.44 -28.96 -27 -28.64 -17.34
Net margin -6,809.29% -8,834.36% -14,168.15% -13,790.78% -14,337.62% - -1,114.55% -454.03%
EPS 2 -2.620 -0.4500 -0.4000 -0.4000 -0.6000 -0.5400 -0.4700 -0.5500
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/30/20 3/31/21 3/31/22 3/31/23 4/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 0.033 0.05 0.033 0.03 0.021 0.056 0.049 0.042 0.046 0.065
EBITDA - - - - - - - - - -
EBIT 1 -3.929 -5.666 -3.152 -4.695 -6.521 -5.556 -4.295 -5.461 -8.157 -14
Operating Margin -11,906.06% -11,332% -9,551.52% -15,650% -31,052.38% -9,921.43% -8,765.31% -13,002.38% -17,732.61% -21,544.62%
Earnings before Tax (EBT) 1 -3.826 -5.846 -3.82 -4.851 -6.385 -4.389 -3.661 -4.909 -7.816 -12.58
Net income 1 -3.826 -5.846 -3.82 -4.851 -6.385 -4.389 -3.661 -4.909 -7.816 -12.58
Net margin -11,593.94% -11,692% -11,575.76% -16,170% -30,404.76% -7,837.5% -7,471.43% -11,688.1% -16,991.3% -19,347.69%
EPS 2 -0.0800 -0.1200 -0.0800 -0.1000 -0.1300 -0.0900 -0.0800 -0.1000 -0.1600 -0.2600
Dividend per Share - - - - - - - - - -
Announcement Date 11/15/21 3/31/22 5/13/22 8/15/22 11/14/22 3/31/23 5/15/23 8/14/23 11/14/23 4/1/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 1.240 1.450 1.190 0.8000 - - - -
Cash Flow per Share - - - - - - - -
Capex 0.07 0.02 - - - - - -
Capex / Sales 48.57% 13.5% - - - - - -
Announcement Date 3/30/20 3/31/21 3/31/22 3/31/23 4/1/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.4282 USD
Average target price
2.75 USD
Spread / Average Target
+542.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AIM IMMUNOTECH INC. Stock AIM ImmunoTech Inc.
-2.66% 21.37M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AIM Stock
  4. Financials AIM ImmunoTech Inc.